BRIEF-Allogene Granted Three U.S. FDA Fast Track Designations (Ftd) For Allo-329

Reuters
07 Apr
BRIEF-Allogene Granted Three U.S. FDA Fast Track Designations (Ftd) For Allo-329

April 7 (Reuters) - Allogene Therapeutics Inc ALLO.O:

  • ALLOGENE GRANTED THREE U.S. FDA FAST TRACK DESIGNATIONS (FTD) FOR ALLO-329, A NEXT-GENERATION DUAL-TARGETED CD19/CD70 ALLOGENEIC CAR T, FOR THE TREATMENT OF LUPUS, MYOSITIS AND SCLERODERMA

  • ALLOGENE THERAPEUTICS INC: EXPECTS TO INITIATE PHASE 1 RESOLUTION BASKET TRIAL IN MID-2025

Source text: ID:nGNX92VkxQ

Further company coverage: ALLO.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10